TY - JOUR
T1 - Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease
AU - Ángel, Gómez Sámano Miguel
AU - Paola, Vargas Abonce Valerie
AU - Froylan David, Martínez Sánchez
AU - Lucía, Palacios Báez
AU - Juan Mauricio, Vera Zertuche
AU - María Fernanda, Navarro Flores
AU - Guadalupe, Morales García Mariana
AU - Jorge Ignacio, Fonseca Correa
AU - Julia María, Zuarth Vázquez
AU - Olynka, Vega Vega
AU - Ricardo, Correa Rotter
AU - Rodolfo, Rincón Pedrero
AU - Luis E, Morales Buenrostro
AU - Josefina, Alberú Gómez
AU - Berenice, Ramírez González Julia
AU - Lizette, Pacheco Domínguez Reyna
AU - Malaquías, López Cervantes
AU - de los Ángeles, Mendoza de la Garza María
AU - Victoria, Baeza Arias Yolanda
AU - Ángeles, Espinosa Cuevas
AU - Guadalupe, López Carrasco
AU - Angelina, López Estrada
AU - Elizabeth, Guillén Pineda Luz
AU - Francisco J, Gómez Pérez
AU - Daniel, Cuevas Ramos
N1 - Funding Information:
The authors received funding from the department of Endocrinology and Metabolism of the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Publisher Copyright:
© The Author(s), 2021.
PY - 2021
Y1 - 2021
N2 - Background and aims: Oxidative stress (OS) induces the production of fibroblast growth factor 21 (FGF21). Previous data have revealed that FGF21 protects cells from OS injury and death, making it a potential therapeutic option for many diseases with increased OS. However, the association of this growth factor with OS markers in humans with chronic kidney disease (CKD) remains unknown. This study aims to evaluate the association of serum FGF21 with serum total antioxidant capacity (TAC) and oxidized low-density lipoproteins (OxLDL) in subjects in different stages of kidney disease. Methods: This is a cross-sectional study that included 382 subjects with different stages of CKD, irrespective of type 2 diabetes (T2D) diagnosis. Associations of serum FGF21 with OxLDL, TAC, sex, age, body mass index (BMI), fasting plasma glucose, estimated glomerular filtration rate (eGFR), T2D, and smoking, were evaluated through bivariate and partial correlation analyses. Independent associations of these variables with serum FGF21 were evaluated using multiple linear regression analysis. Results: Serum FGF21 was significantly and positively correlated with age (r = 0.236), TAC (lnTAC) (r = 0.217), and negatively correlated with eGFR (r = −0.429) and male sex (r = −0.102). After controlling by age, sex, BMI, T2D, smoking, and eGFR; both TAC and OxLDL were positively correlated with FGF21 (r = 0.117 and 0.158 respectively, p < 0.05). Using multiple linear regression analysis, eGFR, male sex, T2D, OxLDL, and TAC were independently associated with serum FGF21 (STDβ = −0.475, 0.162, −0.153, 0.142 and 0.136 respectively; p < 0.05 for all) adjusted for age, BMI, smoking, and fasting plasma glucose. Conclusion: A positive association between serum FGF21 and OS has been found independently of renal function in humans. Results from the present study provide novel information for deeper understanding of the role of FGF21 in OS in humans with CKD and T2D; mechanistic studies to explain the association of serum FGF21 with oxidative stress in CKD are needed.
AB - Background and aims: Oxidative stress (OS) induces the production of fibroblast growth factor 21 (FGF21). Previous data have revealed that FGF21 protects cells from OS injury and death, making it a potential therapeutic option for many diseases with increased OS. However, the association of this growth factor with OS markers in humans with chronic kidney disease (CKD) remains unknown. This study aims to evaluate the association of serum FGF21 with serum total antioxidant capacity (TAC) and oxidized low-density lipoproteins (OxLDL) in subjects in different stages of kidney disease. Methods: This is a cross-sectional study that included 382 subjects with different stages of CKD, irrespective of type 2 diabetes (T2D) diagnosis. Associations of serum FGF21 with OxLDL, TAC, sex, age, body mass index (BMI), fasting plasma glucose, estimated glomerular filtration rate (eGFR), T2D, and smoking, were evaluated through bivariate and partial correlation analyses. Independent associations of these variables with serum FGF21 were evaluated using multiple linear regression analysis. Results: Serum FGF21 was significantly and positively correlated with age (r = 0.236), TAC (lnTAC) (r = 0.217), and negatively correlated with eGFR (r = −0.429) and male sex (r = −0.102). After controlling by age, sex, BMI, T2D, smoking, and eGFR; both TAC and OxLDL were positively correlated with FGF21 (r = 0.117 and 0.158 respectively, p < 0.05). Using multiple linear regression analysis, eGFR, male sex, T2D, OxLDL, and TAC were independently associated with serum FGF21 (STDβ = −0.475, 0.162, −0.153, 0.142 and 0.136 respectively; p < 0.05 for all) adjusted for age, BMI, smoking, and fasting plasma glucose. Conclusion: A positive association between serum FGF21 and OS has been found independently of renal function in humans. Results from the present study provide novel information for deeper understanding of the role of FGF21 in OS in humans with CKD and T2D; mechanistic studies to explain the association of serum FGF21 with oxidative stress in CKD are needed.
KW - chronic kidney disease
KW - fibroblast growth factor 21
KW - glomerular filtration rate
KW - oxidative stress
KW - serum total antioxidant capacity
UR - http://www.scopus.com/inward/record.url?scp=85103398384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103398384&partnerID=8YFLogxK
U2 - 10.1177/20420188211001160
DO - 10.1177/20420188211001160
M3 - Article
C2 - 33854753
AN - SCOPUS:85103398384
SN - 2042-0188
VL - 12
JO - Therapeutic Advances in Endocrinology and Metabolism
JF - Therapeutic Advances in Endocrinology and Metabolism
ER -